Can FDA Reinvent Inspections?

A plant inspection backlog caused by COVID-19 restrictions threatens innovation and public health. Now pressured to step up on-site inspections, will FDA embrace new methods?

Pressure is mounting on FDA to step up the pace of on-site inspections that were postponed due to COVID-19 safety issues and restrictions. An open question is whether the agency will use new remote auditing technologies to improve its ability to inspect facilities during the COVID-19 pandemic.

Read this article in BioPharm International's Regulatory Sourcebook March 2021 eBook.

Article details

BioPharm International
eBook: Regulatory Sourcebook, March 2021
March 2021
Pages: 4–5

Citation

When referring to this article, please cite it as: A. Shanley, "Can FDA Reinvent Inspections, BioPharm International Regulatory Sourcebook eBook (March 2021).

Articles in this issue

almost 5 years ago

Article

It Takes a Bio/Pharma Village

almost 5 years ago

Article

Enabling the Virtual Human Through Physiologically-based Pharmacokinetic Modeling

almost 5 years ago

Article

Overcoming Challenges to Biopharmaceutical Development and Manufacture with Science- and Risk-Based Strategies

almost 5 years ago

Article

Extrapolating Data from Adult Clinical Trials to Advance Pediatric Drug Development

almost 5 years ago

Article

Collaborative Efforts Address Key Data Integrity Challenges

almost 5 years ago

Article

Growing Pipeline of Antisense Oligonucleotides Prompts Guidance

almost 5 years ago

Article

Gene Therapies Target Neurodegenerative Diseases

almost 5 years ago

Article

A Real-World Approach to Evaluating Cleanroom Garments

almost 5 years ago

Article

FDA 2021 Guidance Agenda Sees Focus on Generics

almost 5 years ago

Article

Regulatory and Standard Setting Organizations Directory

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!